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Background: To be clinically useful, an instrument assessing health-related quality of life (HRQOL) should be easy
to understand and quick to answer. Few instruments have been designed to be short, simple, and easily
understandable by patients from all educational levels. The aim of the present study was to evaluate the
psychometric properties of a brief general instrument developed to assess HRQOL.
Methods: Results from a preliminary study regarding the initial development of the Barretos Short Instrument for
Assessment of Quality of Life (BSIqol) with 80 cancer patients are presented. Out of all the patients, 59 completed
the BSIqol on two occasions in order to evaluate the reproducibility test-retest. Validity analyses were done
comparing scores from BSIqol with EORTC QLQ-C30 and Edmonton Symptom Assessment System (ESAS). In
addition, BSIqol scores were analyzed in function of ECOG-PS, work activity, and financial income.
Results: BSIqol demonstrated good internal consistency (Cronbach's α = 0.79) and adequate test-retest reliability,
with intraclass coefficient correlation (ICC) varying from 0.736 to 0.946. There were adequate correlations between
scores of BSIqol, EORTC QLQ-C30 and ESAS. The BSIqol was capable of discriminating between clinical subgroups,
with different ECOG-PS and work activity. Patients completed the BSIqol in a median time <2 min. Only one patient
reported some difficulty to answer the instrument.
Conclusions: BSIqol seems to be a straightforward and useful instrument for rapidly assessing HRQOL from cancer
patients. Further studies are necessary to evaluate BSIqol in different populations and also to assess its
responsiveness and define its minimal clinically important differences.
Keywords: Quality of life, Questionnaire development, Reliability, Validity, CancerBackground
Besides estimates of survival, it is necessary to include
measures of health-related quality of life (HRQOL) to
assess the outcomes of cancer treatment. Several tools
have been developed for the assessment of HRQOL in
oncology. In general, such tools are classified in generic,
cancer-specific or cancer-site specific. The two most
widely used questionnaires are the European Organization* Correspondence: caredupai@gmail.com
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reproduction in any medium, provided the orfor the Research and Treatment of Cancer Quality of
Life Questionnaire Core 30 (EORTC QLQ-C30) [1] and
the Functional Assessment of Cancer Therapy-General
(FACT-G) [2,3]. Both questionnaires are considered
“core” instruments that can be supplemented by ‘specific
modules’ targeting neoplasms, symptoms or specific
treatments [3].
The main advantage of measuring HRQOL is the obser-
vation of the treatment clinical benefit according to
patients’ own perspective. To be clinically useful, an in-
strument assessing HRQOL should be easy to understand
and quick to be answered [4]. In this regard, currently,
one can notice the lack of short instruments. The bigtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of items, is the difficulty in turning them into multidimen-
sional instruments. In addition to that, simplified instru-
ments tend to have lower levels of reproducibility [5].
Another limiting factor for the routine use of HRQOL
questionnaires is that patients with low educational level
find them difficult to use. These patients have not been
systematically included in the questionnaires validation
studies. Few researchers [6,7] have dedicated time for
the development of instruments targeted to this group
of individuals, which, unfortunately, is still very common
in Brazil.
The aim of the present study was to develop and valid-
ate a simplified instrument, comprised of only 6 items,
which could be answered in a quick manner by people
with different levels of education. Thus, the intention
was to use general questions, with short explanatory
texts and greater visual impact, using colors that would
make it easier for the identification of values on a visual
analogue scale ranging from 0 to 10.
Methods
Instrument development
The instrument was developed on the premise that the
single item “feeling of well being”, from the ESAS [8]
showed an adequate correlation with various domains of
HRQOL [9]. Thus, the instrument has been designed in
an attempt to use the understanding of the well-being
concept from a patient’s standpoint. For the develop-
ment of BSIqol, we considered HRQOL as the subjective
perception, reported by the patient, about the impact of
the disease and/or its treatment in their daily life, neces-
sarily encompassing the dimensions of physical, psycho-
logical and social well-being [10].
Whereas HRQOL as a multidimensional construct,
which necessarily includes the physical, emotional, social
and functional aspects, we sought to create a simple in-
strument, with few items that would measure the
HRQOL quickly and that could have applicability in
daily oncology. The BSIqol is a generic instrument, cre-
ated in a consensus meeting between two of the authors
(CEP and BSRP), and improved along the subsequent
steps.
Initially the BSIqol was answered by healthy people
(n = 6), well-educated advanced cancer patients (n = 5),
and than by oncology physicians (n = 5) and nursing
professionals (n = 5). They could critique and suggest
changes in the structure of the instrument in order to
facilitate their understanding.
All the staff have formally rated the instrument using
a standardized form. The BSIqol was initially designed
in four ways: (1) using Likert type responses, (2) visual
analogue scale, (3) visual numeric scale without colors,
and (4) visual numeric scale with colors. Fourteenrespondents (14/21; 67%) said they preferred the visual
numeric scale, with added colors. No respondent
reported having had difficulty understanding the instru-
ment items. Among healthy people and cancer patients,
there were no suggestions as to delete items, however,
concerning the item 3, it was suggested to include the
evaluations of optimism/pessimism. Two healthy people,
a patient and a doctor, in order to make the instrument
more clear, suggested removing words that made refer-
ence to some specific symptoms (fatigue, pain, vomiting,
dyspnea) in the original instrument (item 2), and include
more general items ("several unpleasant feelings"/"I don’t
feel anything bad"). Among the five doctors, one sug-
gested that the term "one week" could be changed from
the beginning to the end of the sentences (items 1–3),
and another doctor suggested changing the term "in
general" for "as a whole" in item one. A nurse requested
that items 5 and 6 were evaluated together. Another
nurse suggested to be added to item 5, in parentheses,
the information "bathing, dressing up, combing your
hair, eating, etc.," not present in the original instrument.
The BSIqol was reassessed once again by responders
after the changes being carried out.
The instrument features six items arranged in figures,
with questions written in large letters and short sen-
tences. The BSIqol provides answers on a numerical
scale ranging from 0 (worst) to 10 (best). We employed
the color concept to facilitate the understanding of the
respondents. The colors used were the colors often used
in traffic lights (red, yellow and green). Answers may
range from dark red (0), gradually moving towards yel-
low (medium) up to dark green (10) (Additional file 1
and Additional file 2).
Another feature of the instrument is that it contains sev-
eral words and/or phrases designed to collect responses
within the same domain. These words and/or phrases are
located close to 0 and 10. For example, the item assessing
the emotional domain (item 3), displays the words “sad-
ness”, “anxiety”, “pessimism” and “unwilling to live” close
to 0 (dark red). This same item, features the words “happi-
ness”, “tranquility”, “optimism” and “great will to live”
close to 10 (dark green). The words “terrible”, “more or
less” and “excellent” were also included in this same item,
respecting the positioning of the colors.
The items in the questionnaire being studied assess
the HRQOL of patients during the period composed of
the seven previous days. The original instrument is
described in Additional file 1 and the version translated
into English as Additional file 2. Questions for each item
are listed below:
Item 1 - Think about your life as a whole. What grade
would you give to your sense of well-being during the
last week?
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would you give to your sense of physical well-being
during the last week?
Item 3 - Think about your emotional side. What grade
would you give to your sense of emotional well-being
during the last week?
Item 4 - Think about the people you love, those that
really matter to you. Overall, how is your relationship
with them?
What grade would you give to your ability to:
Item 5 – Take care of yourself (bathing, dressing up,
combing your hair, eating, etc.)
Item 6 – Work
With the intent of making it easier for comparisons
between other instruments and to increase its clinical
applicability, BSIqol scores were converted into a scale
ranging from 0 to 100, with higher scores indicating bet-
ter HRQOL, and calculated as follows:
BSIqol global ¼ item 1þ item 2þ item 3þ Item 4ð½
þItem 5þ Item 6Þ=6  100
BSIqol physical ¼ item 2 100
BSIqol emotional ¼ item 3 100
BSIqol social ¼ item 4 100
BSIqol functional ¼ item 5þ item 6ð Þ=2½   100
Study setting and population
We interviewed 80 patients undergoing systemic antineo-
plastic treatment in the Department of Clinical Oncology
at the Barretos Cancer Hospital (BCH) (Barretos, SP,
Brazil), from April to June 2012. Patients were recruited
in the chemotherapy/infusion room and the hormone
therapy outpatient room. The inclusion criteria com-
prised of having been diagnosed with cancer and under-
going a systemic antineoplastic treatment, regardless of
the histological type or stage of cancer. The exclusion cri-
teria included the presence of significant neuropsychiatric
disorder that could prevent patients from answering the
study questionnaires, and also the refusal in taking part
of the study. All patients agreed to participate in the
study and signed a consent form. This project was




The questionnaires EORTC QLQ-C30, ESAS and BSIqol
were applied by a single interviewer trained for the task.Regarding BSIqol, each item was printed on A4 paper
(210 mm x 297 mm) and laminated afterwords. Items 5
and 6 were put together on a single sheet. The items
were answered by the patients using special pens, which
allowed for the reuse of the survey.Analytic strategies
Internal consistency and test-retest reliability
Reliability was assessed using Cronbach’s alpha coeffi-
cient, which should be ≥ 0.70 to be considered adequate
[11].
A sample of 54 patients answered the BSIqol twice, to
evaluate the test-retest reliability. To be submitted to re-
test, patients needed to be clinically stable and free of
stressful events since the first evaluation. It was assessed
using the intraclass correlation coefficient (ICC) with a
retest interval of 2 h to 7 days of the initial assessment.
The mean time (± SD) for the retest was 32.6 (± 65)
hours. Test-retest reliability was considered adequate
when ICC ≥ 0.70 [11].Validity analysis
Construct validity was assessed using exploratory fac-
tor analysis of principal components with varimax
orthogonal rotation. The Kaiser-Meyer-Olkin (KMO)
Test and Bartlett’s Test of Sphericity were performed
to indicate the degree of data susceptibility to factor
analysis. To determine the number of factors to be
extracted, we used the “scree test” proposed by Cattel
and Jaspers [12].
Construct validity was assessed by measuring conver-
gent and discriminative validity. For the convergent valid-
ation analysis, the BSIqol score was expected to be
positively correlated with the global and functional scores
of the EORTC QLQ-C30. Also, the BSIqol social was cor-
related with family income (measured in Brazilian mini-
mum wages). Regarding discriminative validity, BSIqol
was expected to be negatively correlated with the Total
Symptom Distress Score (TSDS) of the ESAS (sum of the
scores for pain, fatigue, nausea, anxiety, depression, drow-
siness, anorexia and dyspnea), the ESAS emotional score
(depression and anxiety mean scores) and the ESAS
physical score (mean scores for pain, fatigue, nausea,
drowsiness, anorexia, and dyspnea). In addition, BSIqol
functional was also expected to be negatively correlated
with Eastern Cooperative Oncology Group (ECOG) per-
formance status scores.
Known-group validity was assessed by comparing the
BSIqol scores according to different levels of ECOG-PS
and also in relation to the working activity (active vs. in-
active). Mann–Whitney and Kruskal-Wallis tests were
used to examine group differences.
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The time taken to answer the BSIqol was measured for
78 patients, who were asked about the likely issues they
found when responding the instrument. The difficulties
were categorized as (a) none, (b) some or (c) a lot. An-
other measurement examined was the missing data.
Sample size estimation
The sample size was estimated based on the assumption
that would be adequate between three to twenty respon-
dents for each single item in the instrument to be tested
[13]; this equates to between 18 and 120 subjects for the
BSIqol. In addition, 50 subjects may be considered an
adequate sample size for test–retest reliability [14,15].
Results
Eighty cancer patients were assessed and the most com-
mon primary tumors were breast (38/80; 47.5%) and
prostate (20/80; 25%). The median age was 58 years
(23–83 years). Most patients were women (57/80; 71%),
Caucasian (65/80; 81%) and described inactivity at work
(54/80; 68%). Regarding their marital status, 45 were mar-
ried (45/80; 56%). The majority of patients were ECOG-
PS 0 or 1 (69/80; 86%). TNM staging was IV in 38
patients (38/80; 48%). Half of the patients (40/80; 50%)
were on chemotherapy and the other half was undergoing
hormone therapy. In regard to their educational level, 50
patients (50/80; 62.5%) had low educational level, being
regarded as illiterate and/or with only primary education
completed (total ≤ 4 years of formal schooling). Patient
characteristics are described in Additional file 3.
Descriptive statistics
The median (25th-75th) scores of the BSIqol global were
70 (60.4-84.5), BSIqol physical 60 (50–80), BSIqol emo-
tional 70 (40–87.5), BSIqol functional 75 (60–90) and
BSIqol social 90 (80–100).
Internal consistency and test-retest reliability
The Cronbach’s alpha of the instrument was 0.79
(Table 1) and ICC varied from 0.736 to 0.946 (Table 2).Table 1 Internal consistency of BSIqol (N = 80)
BSIqol Mean (SD) Median (25th-75th)
Global 70.2 (16.5) 70 (60.5–84.5)
Items
1 6.6 (2.16) 6.5 (5–8)
2 6.2 (2.30) 6 (5–8)
3 6.05 (2.72) 7 (4–8.5)
4 8.62 (2.01) 9 (8–10)
5 8.98 (1.91) 10 (9–10)
6 5.66 (2.83) 6 (3.5-8)Validity analysis
The KMO index (0.80) indicated that there was suffi-
cient level of factorability. The Bartlett's sphericity test
(p < 0.001) indicated that the correlation matrices were
not identical to the factor structure matrices. Both tests
revealed that data were appropriate for factor analysis.
The “scree test” identified three factors that explained a
total variance of 78.5%. Factor 1 was considered as
“well-being”, factor 2 as the “functional” and factor 3 as
“social”. However, for the analysis of the validation cri-
teria of the BSIqol described next, and because it is more
useful clinically, we chose to continue considering the
Factor 1 divided as BSIqol emotional and BSIqol physical
(Table 3).
There was a high correlation between the BSIqol global
score and global health score of the EORTC QLQ-C30
(r = 0.767; p < 0.001). In the same manner, the BSIqol glo-
bal correlated itself well with the global functional scale
(r = 0.809; p < 0.001) and global symptoms (r = −0.678;
p < 0.001) (Table 4).
The BSIqol physical was the domain that best corre-
lated with the physical functioning subscales (r = 0.669;
p < 0.001) and role functioning (r = 0.715; p < 0.001)
(Table 4).
BSIqol emotional was the domain with the highest
value for “r” in relation to emotional functioning sub-
scale of the EORTC QLQ-C30 (r = 0.774; p < 0.001)
(Table 4).
BSIqol functional provided adequate correlation with
the global functional domain (r = 0.553; p < 0.001), phys-
ical functioning (r = 0.579; p < 0.001) and role function-
ing (r = 0.529; p < 0.001) (Table 4).
While having a low correlation coefficient, the BSIqol
social correlated significantly with the social functioning
subscale (r = 0.223; p < 0.05) and with the financial diffi-
culties domain (r = −0.323; p < 0.001) (Table 4).
Regarding the ESAS, all domains of BSIqol correlated
negatively with TSDS. However, the highest correlation
coefficients were related to the BSIqol global (r = −0.708;
p < 0.001), BSIqol physical (r = −0.679; p < 0.001) and








Table 2 Test-retest reliability analysis of BSIqol (N = 54)
BSIqol ICC 95% CI p-value
Global 0.946 0.907–0.969 <0.001
Physical 0.900 0.828–0.942 <0.001
Emotional 0.851 0.744–0.913 <0.001
Functional 0.932 0.883–0.960 <0.001
Social 0.736 0.553–0.847 <0.001
Legend: ICC intraclass correlation coefficient.
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physical were BSIqol global (r = −0.670; p < 0.001) and
BSIqol physical (r = −0.699; p < 0.001). Similarly, the field
that best correlated as ESAS emotional was BSIqol emo-
tional (r = −0.593; p < 0.001) (Table 5).
BSIqol scores were negatively correlated with the
ECOG-PS. As expected, the domain with the highest
correlation coefficient was BSIqol functional (r = −0.714;
p < 0.001) (Additional file 4).
In an interesting way, BSIqol social was the only one
that correlated in a statistically significant way with
patients’ family income (r = 0.208; p < 0.05) (Additional
file 4).
All domains of BSIqol, with the exception of BSIqol
social, showed different medians between the different
statuses of ECOG-PS. There was a progressive worsen-
ing of the BSIqol scores such as global, physical, emo-
tional and functional as the functional performance
worsened (Table 6).
Regarding the working activity, one could have
observed that patients in active work had higher global,
emotional and functional BSIqol scores. We emphasize
the difference found in the median scores of BSIqol
functional among individuals in active and inactive work
(90 and 70, respectively) (p < 0.001) (Table 7).
Feasibility
The median time to answer BSIqol was 1:47 min (0:48–
4:53). Out of the 78 patients interviewed, only one (1/78;
1.3%) reported having some difficulty in answering the
instrument. The same patient, who was illiterate,Table 3 Principal component analysis of BSIqol items







% of variance 49.9 15.5 13.1
Cronbach’s α 0.80 0.60 NA
*p < 0.001. Legend: NA not applicable. Factorial loads <0.4 were omitted.reported having great difficulty in answering the EORTC
QLQ-C30, and mentioned that it was easier to answer
the BSIqol in relation to the EORTC QLQ-C30, due to
the fact that the survey instrument displayed colors.
Regarding the EORTC QLQ-C30, 4 patients reported
having some difficulty and 1 patient had great difficulty
answering it (completely with difficulty 5/78; 6.4%). Out
of these 5 patients, 2 were illiterate and 3 of them had
had ≤ 4 years of formal schooling.
There was no missing data (“missing values”) in rela-
tion to BSIqol.
Discussion
The authors developed a new instrument to measure
HRQOL. The BSIqol was designed to be a generic ques-
tionnaire and was validated in a sample of cancer
patients. The great advantage of the proposed instru-
ment is its likely clinical usefulness since it was
answered quickly and without difficulty by the intervie-
wees, even in a population having low educational level
where approximately 60% had less than four years of for-
mal schooling and 10% were illiterate.
The BCH is exclusively dedicated to oncology and
serves a needy population in terms of financial
resources, originated from all corners of Brazil. The de-
velopment of BSIqol comes to fill a gap in clinical prac-
tice observed by the authors of this research, where
many patients have difficulty answering instruments that
assess “patient-reported outcomes”, even instruments
that have been appropriately validated in the country.
This is probably because the population of low socioeco-
nomic level treated in the hospital does not reflect the
populations subjected to validation studies often con-
ducted around the country.
Considering HRQOL within a multidimensional con-
cept, the instruments proposed for its measurement
must assess at least the physical, emotional, functional
and social aspects [16]. To this end, the tools developed
are mostly long and sometimes complex, or too stressful
for some individuals.
The main advantage in measuring HRQOL is the ob-
servation of clinical benefits on the treatment from the
patient’s own perspective. In oncology, the two most
widely used instruments in research are EORTC QLQ-
C30 and FACT-G [3]. The EORTC QLQ-C30, comprised
of 30 items, and FACT-G, with 28 items, are usually
answered within 5 to 10 min. The BSIqol was answered
in a median time of <2 min, which was very relevant,
considering the low socioeconomic level of the popula-
tion assessed in this study.
The search for instruments that would measure the
HRQOL with few items is not new [17-19]. Some instru-
ments with few items proved to be valid in some specific
situations; however, they are still rarely used [20-22].
Table 4 Spearman correlation analysis between BSIqol domains and EORTC QLQ-C30
EORTC QLQ-C30 BSIqol
Global Physical Emotional Functional Social
Global health status 0.767** 0.639** 0.620** 0.534** 0.472**
Function global 0.809** 0.724** 0.725** 0.553** 0.354**
Physical functioning 0.664** 0.669** 0.465** 0.579** 0.205
Role functioning 0.704** 0.715** 0.560** 0.529** 0.272*
Emotional functioning 0.658** 0.440** 0.774** 0.317** 0.422**
Cognitive functioning 0.288 0.335** 0.363** 0.058 0.168
Social functioning 0.364** 0.330** 0.291** 0.296** 0.223*
Symptom global −0.678** −0.701** −0.565** −0.477** −0.259*
Financial difficulties −0.328** −0.205 −0.228* −0.304** −0.323**
*p < 0.05 **p < 0.01. _Underline indicates a pair of scales that should correlate theoretically.
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have higher response rate (when mailed to patients) and
lower rates of unanswered items, compared with long
questionnaires [23,24]. Moreover, short questionnaires
would possibly be less of a burden to patients and would
facilitate the operational logistics involved in health ser-
vices [25].
The reduction in items from longer questionnaires in
order to make them shorter has proved to be feasible in
previous studies, and the short instruments did not lose
their psychometric characteristics [26,27]. One instru-
ment worth mentioning is the Quick-FLIC, with 11
items, whose total score showed good correlation with
the EORTC QLQ-C30 global health, with correlation
coefficients ranging from 0.71 to 0.77 [28]. The global
score of the Quick-FLIC may vary from 0 to 100 and it
was more clinically relevant than the scores of individual
items. Similarly, the BSIqol global score correlated with
the EORTC QLQ-C30 global health with a high correl-
ation coefficient (r = 0.76). As with the Quick-FLIC glo-
bal score, we believe the global score is the most useful
index extracted from BSIqol for future studies and for
use in clinical practice.
Some studies suggest that social support may interfere
with HRQOL [29,30]. The BSIqol social domain specific-
ally assessed interpersonal relationships based on the
theoretical premise that a good relationship with people
considered important to patients would be associated






*p < 0.05 **p < 0.01. _Underline indicates a pair of scales that should correlate theo
Legend: ESAS Edmonton Symptom Assesment System.significantly with the social functional domain of the
EORTC QLQ-C30, however, the correlation coefficient
was found to be low (r = 0.223). This can be explained in
that the EORTC QLQ-C30 assesses the social impact on
HRQOL caused by cancer or its treatment; the BSIqol,
however, upon assessing the interpersonal relationships,
does not associate them with the disease or its treat-
ment. The authors believe that problems in interper-
sonal relationships may impact HRQOL regardless
whatever its cause may be. Interestingly enough, we
observed that the BSIqol social scale correlated with the
financial difficulties subscale and also correlated nega-
tively with the family income of patients. This finding
points to the association between problems in interper-
sonal relationships and financial difficulties. Financial
difficulties secondary to cancer are common [31] and
may interfere with HRQOL [32].
The BSIqol emotional showed high correlation coeffi-
cient with EORTC QLQ-C30 emotional functioning
domain (r = 0.775) and also with the ESAS-emotional
(r = −0.593). Similarly, the BSIqol physical scale corre-
lated with the physical functioning (r = 0.669), role
functioning (r = 0.715), global symptoms (r = −0.701)
and the ESAS-physical (r = −0.699). These correlations
point to an adequate validation of the physical and
emotional BSIqol domains.
In spite of the adequate correlation coefficients (r > 0.5)
displayed by BSIqol functional when correlated with the







Table 6 Median scores (25th-75th) of BSIqol domains
between different Performance Status according to ECOG
BSIqol ECOG - PS
0 (n = 34) 1 (n = 35) 2/3 (n = 11) p-value
Global 85 (72.5–91.7) 65 (57.5–73.3) 53.3 (38.3–67.5) <0.0001
Physical 80 (60–90) 50 (50–70) 40 (25–60) <0.0001
Emotional 75 (60–90) 50 (40–80) 30 (10–65) <0.0001
Functional 92.5 (80–100) 70 (60–75) 55 (42.4–75) <0.0001
Social 100 (90–100) 90 (80–100) 80 (50–100) 0.108
Legend: ECOG –PS Eastern Cooperative Oncology Group performance status.
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the BSIqol functional, we found the highest correlation
with ECOG-PS when we correlated the functional per-
formance with BSIqol functional (r = −0.714). Further-
more, functional BSIqol scores were significantly higher
in patients who maintained work activity, in relation to
those inactive at work. In this analysis, the BSIqol func-
tional was the domain most associated with work
activity.
In addition to the color concept, the BSIqol uses short
and simple sentences, with large letters. Each item is
shown on a different page, except for items 5 and 6
(functional domain), shown on a single page because
they are interrelated with one another. The authors be-
lieve that such “layout” facilitates the understanding of
patients, since only one of the respondents reported
some difficulty to understand it. The Moorehead-Ardelt
Quality of Life Questionnaire is an instrument originally
developed to measure HRQOL in obese patients after
surgery. This questionnaire uses symbols and colors that
facilitate the understanding of patients. It is believed that
such peculiarities made the instrument have a wide
spread use in certain corners of the world due to its con-
venience and ease of being understood [33]. In the
present study, we chose the colors red, yellow and green,
because they are related to traffic signs, possibly being
considered as a universal language.
This preliminary study has some limitations. One of
them is that the questionnaire responsiveness of was not
evaluated. Another limitation is the lack of dataTable 7 Median scores (25th-75th) of BSIqol domains
between work active and inactive patients
BSIqol Work activity
Active Inactive p-value
Global 78.3 (65.8–89.1) 68.3 (54.2–76.7) 0.005
Physical 70 (45–85) 60 (50–80) 0.554
Emotional 70 (55–90) 60 (30–80) 0.033
Functional 90 (75–97.5) 70 (55–80) <0.001
Social 100 (90–100) 90 (70–100) 0.198
*p < 0.05 **p < 0.01.regarding the minimum difference in scores that are
clinically significant to the patient. While this study is
preliminary in nature, further studies are necessary to
clarify the mentioned limitations.
We believe that the major contribution posed by this
study is to show the feasibility as for the development of
very short instruments with good reliability. Further-
more, the characteristics of the instrument (use of col-
ors, one item per page, several words/phrases showing
the same domain, etc.) could be employed as a model
for future instruments.Conclusions
We developed a simplified HRQOL measuring tool con-
taining only six items, which is easily understood by
patients and easy to be applied. The instrument has
demonstrated adequate psychometric characteristics,
with good internal consistency and criterion validation.
Given the aforementioned characteristics, the BSIqol
displays relevant potential for application in oncology
practice. Further studies are needed to evaluate the psy-
chometric characteristics in other populations and assess
the instrument responsiveness.Additional files
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